Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
New England Journal of Medicine · 18.12.2025 · 393 (24) · 2409-2420
DOI: 10.1056/nejmoa2505928 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 18.12.2025. Verfasst von Stephen J Nicholls und 27 weiteren Autor:innen. Beteiligte Einrichtung: Victorian Heart Institute, Monash University, Melbourne, VIC, Australia. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Diabetes Mellitus, Type 2, Immunoglobulin Fc Fragments, Recombinant Fusion Proteins. Die Arbeit wurde bisher 261-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Eli Lilly and Company.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Victorian Heart Institute, Monash University, Melbourne, VIC, Australia.
- Eli Lilly, Indianapolis.
- Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York.
- University of North Carolina, Chapel Hill.
- Interdisciplinary Research Center "Health Science," Sant'Anna School of Advanced Studies, Pisa, Italy.
- Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine, Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle.
ORCID-Profile: Michael A Nauck, Steven E Nissen, Naveed Sattar, Linong Ji
Förderung
- Eli Lilly and Company
Zitieren
APA
Nicholls, S. J., Pavo, I., Bhatt, D. L., Buse, J. B., Del Prato, S., Kahn, S. E., Lincoff, A. M., McGuire, D. K., Miller, D., Nauck, M. A., Nishiyama, H., Nissen, S. E., Sattar, N., Weerakkody, G., Wiese, R. J., Zinman, B., Zoungas, S., Basile, J., Davies, M. J., …, & SURPASS-CVOT Investigators (2025). Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. New England Journal of Medicine, 393(24), 2409-2420. https://doi.org/10.1056/nejmoa2505928
Vancouver
Nicholls SJ, Pavo I, Bhatt DL, Buse JB, Del Prato S, Kahn SE, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. New England Journal of Medicine. 2025;393(24):2409-2420. doi:10.1056/nejmoa2505928
BibTeX
@article{Nicholls2025,
author = {Nicholls, Stephen J and Pavo, Imre and Bhatt, Deepak L and Buse, John B and Del Prato, Stefano and Kahn, Steven E and Lincoff, A Michael and McGuire, Darren K and Miller, Debra and Nauck, Michael A and Nishiyama, Hiroshi and Nissen, Steven E and Sattar, Naveed and Weerakkody, Govinda and Wiese, Russell J and Zinman, Bernard and Zoungas, Sophia and Basile, Jan and Davies, Melanie J and Giorgino, Francesco and Kellerer, Monika and Ji, Linong and Varkonyi, Tamas and Menon, Venu and Broder, Jonathan C and Herschtal, Alan and D'Alessio, David and SURPASS-CVOT Investigators, SURPASS-CVOT Investigators},
title = {Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes},
journal = {New England Journal of Medicine},
year = {2025},
volume = {393},
number = {24},
pages = {2409--2420},
doi = {10.1056/nejmoa2505928}
}
EUVIMED